COPPOLA, GARY MARK,IWAKI, YUKI,KARKI, RAJESHRI GANESH,KAWANAMI, TOSHIO,KSANDER, GARY MICHAEL,MOGI, MUNETO,SUN, ROBERT
申请号：
ES10720165
公开号：
ES2523734T3
申请日:
2010.05.26
申请国别(地区):
ES
年份:
2014
代理人:
摘要：
A compound of Formula I ': ** Formula ** or a pharmaceutically acceptable salt thereof, wherein: R1 is H, C1-7alkyl, hydroxy, C1-7alkoxy, halogen, -SH, -S-C1-7alkyl or NRaRb ； R2 for each occurrence, is independently C1-7alkyl, halo, NO2, CN, C1-7alkanoylamino, C37cycloalkyl, hydroxy, C1-7alkoxy, haloC1-7alkyl, -NRaRb, C6-10aryl, heteroaryl or heterocyclyl； wherein Ra and Rb for each occurrence are independently H or C1-7alkyl； R3 is A2-R4； R4 is C6-10aryl or a heteroaryl, which may be monocyclic or bicyclic, and which may be optionally substituted with one or more substituents independently selected from the group consisting of hydroxy, hydroxyC1-7alkyl, nitro, -NRaRb, -C ( O) C1-7alkyl, C (O) -O-C1-7alkyl, C17alkoxy, halo, C1-7alkyl, halo-C1-7alkyl, C2-7alkenyl, C6-10aryl, heteroaryl, -NHSO2-C1-7alkyl and benzyl； or R4 is a heterocyclyl which may be optionally substituted with one or more substituents independently selected from the group consisting of oxo, hydroxy, hydroxyC17 alkyl, amino, C (O) -O- C1-7alkyl, C1-7alkoxy, halo, C1- 7alkyl, halo-C1-7alkyl, C6-10aryl, heteroaryl, -NHSO2-C1-7alkyl and benzyl； R5 is H, halo, hydroxy, C1-7alkoxy, halo, C1-7alkyl or halo-C1-7alkyl； and X is OH, -O-C1-7alkyl, -NRaRb, -NHS (O) 2-C1-7alkyl, -NHS (O) 2-benzyl or -O- C6-10aryl； wherein alkyl is optionally substituted with one or more substituents independently selected from the group consisting of C6-10aryl, heteroaryl, heterocyclyl, C (O) NH2, C (O) NH-C1-6alkyl, and C (O) N (C1 -6alkyl) 2； B1 is -C (O) NH- or -NHC (O) -； and A2 is a linear or branched C1-7 alkylene bond or bond； which is optionally substituted with one or more substituents independently selected from the group consisting of halo, C1-7alkoxy, hydroxy, O-Acetate and C3-7cycloalkyl； n is 0, 1, 2, 3, 4 or 5； wherein each heteroaryl is a monocyclic or bicyclic aromatic ring comprising from 5-10 ring atoms selected from carbon atoms and 1 to 5 heteroatoms, and each heterocyclyl is a monocyclic saturated or part
